Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera™ MRD Test in Colorectal Cancer

By In The News
August 22, 2019 in The Headlines

Recommended Posts

In The News

Posted August 22, 2019

- Share

Posted August 22, 2019

SAN CARLOS, Calif., Aug. 22, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the Palmetto MolDX program has proposed a local coverage determination (LCD) for use of Natera's Signatera molecular residual disease (MRD) test in...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219800
2. Jaydee
  16681
3. Kip Powick
  12206
4. deicer
  12171
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.1k
- Total Posts
  
  558.4k

Sign In

Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera™ MRD Test in Colorectal Cancer

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support